evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

7 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 3 · 42.9%Low 2 · 28.6%Moderate 2 · 28.6%High 0 · 0%

Retzius‐sparing RALP vs standard RALP

Urinary continence within 1 week after catheter removal MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer

Retzius‐sparing RALP probably leads to higher urinary continence within 1 week after catheter removal MCID: 5%… compared with standard RALP (moderate certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Urinary continence 3 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer

Retzius‐sparing RALP may leads to higher urinary continence 3 months after surgery MCID: 5% absolute difference compared with standard RALP (low certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Serious adverse events · men (ages > 18 years) with clinically localized prostate cancer

It is very uncertain whether retzius‐sparing RALP changes serious adverse events compared with standard RALP (very low certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Urinary continence 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer

Retzius‐sparing RALP showed no clear difference in urinary continence 12 months after surgery MCID: 5% absolute… compared with standard RALP (moderate certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Potency 12 months after surgery MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer

It is very uncertain whether retzius‐sparing RALP changes potency 12 months after surgery MCID: 5% absolute difference compared with standard RALP (very low certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Positive surgical margins MCID: 5% absolute difference · men (ages > 18 years) with clinically localized prostate cancer

Retzius‐sparing RALP may leads to higher positive surgical margins MCID: 5% absolute difference compared with standard RALP (low certainty).

1 finding from 1 review

Retzius‐sparing RALP vs standard RALP

Biochemical recurrence‐free survival · men (ages > 18 years) with clinically localized prostate cancer

It is very uncertain whether retzius‐sparing RALP changes biochemical recurrence‐free survival compared with standard RALP (very low certainty).

1 finding from 1 review